ARS Pharmaceuticals (SPRY) Stock Forecast, Price Target & Predictions
SPRY Stock Forecast
ARS Pharmaceuticals stock forecast is as follows: an average price target of $23.33 (represents a 69.18% upside from SPRY’s last price of $13.79) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.
SPRY Price Target
The average price target for ARS Pharmaceuticals (SPRY) is $23.33 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $30.00 to $18.00. This represents a potential 69.18% upside from SPRY's last price of $13.79.
SPRY Analyst Ratings
According to 5 Wall Street analysts, ARS Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for SPRY stock is 1 'Strong Buy' (20.00%), 4 'Buy' (80.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
ARS Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 19, 2024 | Josh Schimmer | Cantor Fitzgerald | $30.00 | $14.24 | 110.67% | 117.55% |
| Aug 12, 2024 | Strong Buy | Raymond James | $22.00 | $10.85 | 102.76% | 59.54% |
| Jul 25, 2024 | Ryan Deschner | Raymond James | $18.00 | $10.40 | 73.08% | 30.53% |
| Mar 05, 2024 | Roanna Ruiz | Leerink Partners | $18.00 | $8.65 | 108.09% | 30.53% |
| Dec 13, 2022 | - | Leerink Partners | $14.00 | $7.12 | 96.63% | 1.52% |
The latest ARS Pharmaceuticals stock forecast, released on Aug 19, 2024 by Josh Schimmer from Cantor Fitzgerald, set a price target of $30.00, which represents a 110.67% increase from the stock price at the time of the forecast ($14.24), and a 117.55% increase from SPRY last price ($13.79).
ARS Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 4 |
| Avg Price Target | - | - | $22.00 |
| Last Closing Price | $13.79 | $13.79 | $13.79 |
| Upside/Downside | -100.00% | -100.00% | 59.54% |
In the current month, the average price target of ARS Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to ARS Pharmaceuticals's last price of $13.79. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 08, 2024 | Leerink Partners | Underperform | Underperform | Hold |
| Oct 08, 2024 | Raymond James | Strong Buy | Strong Buy | Hold |
| Sep 09, 2024 | Raymond James | Strong Buy | Strong Buy | Hold |
| Sep 09, 2024 | Dawson James | Underperform | Underperform | Hold |
| Aug 19, 2024 | Cantor Fitzgerald | - | Overweight | Initialise |
| Aug 12, 2024 | Raymond James | Outperform | Strong Buy | Upgrade |
| Jul 25, 2024 | Raymond James | - | Outperform | Initialise |
| Mar 05, 2024 | Leerink Partners | - | Outperform | Upgrade |
| Feb 20, 2024 | William Blair | Market Perform | Outperform | Upgrade |
| Sep 21, 2023 | William Blair | Outperform | Market Perform | Downgrade |
ARS Pharmaceuticals's last stock rating was published by Leerink Partners on Oct 08, 2024. The company gave SPRY a "Underperform" rating, the same as its previous rate.
ARS Pharmaceuticals Financial Forecast
ARS Pharmaceuticals Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $85.29M | $112.09M | $74.07M | $41.90M | $29.59M | $26.23M | $16.19M | $8.70M | $5.32M | $575.00K | $1.00M | $1.00M |
| High Forecast | $169.29M | $222.48M | $147.01M | $83.16M | $58.73M | $52.06M | $32.13M | $10.63M | $13.48M | $1.14M | $1.98M | $1.98M |
| Low Forecast | $26.18M | $34.41M | $22.74M | $12.86M | $9.08M | $8.05M | $4.97M | $6.75M | $634.27K | $176.51K | $306.97K | $306.97K |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 3 | 1 | 1 | 1 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - |
ARS Pharmaceuticals's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. SPRY's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
ARS Pharmaceuticals EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 3 | 1 | 1 | 1 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $-34.56M | $-45.42M | $-30.01M | $-16.98M | $-11.99M | $-10.63M | $-6.56M | $-3.52M | $-2.16M | $-232.99K | $-405.19K | $-405.19K |
| High Forecast | $-10.61M | $-13.94M | $-9.21M | $-5.21M | $-3.68M | $-3.26M | $-2.01M | $-2.73M | $-257.00K | $-71.52K | $-124.38K | $-124.38K |
| Low Forecast | $-68.59M | $-90.15M | $-59.57M | $-33.70M | $-23.80M | $-21.09M | $-13.02M | $-4.31M | $-5.46M | $-462.44K | $-804.25K | $-804.25K |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - |
undefined analysts predict SPRY's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than ARS Pharmaceuticals's previous annual EBITDA (undefined) of $NaN.
ARS Pharmaceuticals Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 3 | 1 | 1 | 1 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $28.27M | $47.88M | $20.62M | $-5.40M | $-11.97M | $-21.02M | $-19.73M | $-22.96M | $-5.58M | $-13.83M | $-10.73M | $-9.60M |
| High Forecast | $64.45M | $109.17M | $47.02M | $-535.40K | $-1.19M | $-2.08M | $-1.95M | $-16.08M | $16.12M | $-1.37M | $-1.06M | $-950.64K |
| Low Forecast | $2.80M | $4.74M | $2.04M | $-12.32M | $-27.29M | $-47.94M | $-44.99M | $-29.85M | $-16.74M | $-31.53M | $-24.48M | $-21.88M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - |
ARS Pharmaceuticals's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. SPRY's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
ARS Pharmaceuticals SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 3 | 1 | 1 | 1 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $27.16B | $35.70B | $23.59B | $13.34B | $9.42B | $8.35B | $5.15B | $2.77B | $1.69B | $183.11M | $318.45M | $318.45M |
| High Forecast | $53.91B | $70.85B | $46.81B | $26.48B | $18.70B | $16.58B | $10.23B | $3.39B | $4.29B | $363.44M | $632.07M | $632.07M |
| Low Forecast | $8.34B | $10.96B | $7.24B | $4.10B | $2.89B | $2.56B | $1.58B | $2.15B | $201.98M | $56.21M | $97.75M | $97.75M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - |
ARS Pharmaceuticals's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to SPRY last annual SG&A of $NaN (undefined).
ARS Pharmaceuticals EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 3 | 1 | 1 | 1 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $0.29 | $0.49 | $0.21 | $-0.06 | $-0.12 | $-0.22 | $-0.20 | $-0.24 | $-0.06 | $-0.14 | $-0.11 | $-0.10 |
| High Forecast | $0.66 | $1.13 | $0.48 | $-0.01 | $-0.01 | $-0.02 | $-0.02 | $-0.17 | $0.17 | $-0.01 | $-0.01 | $-0.01 |
| Low Forecast | $0.03 | $0.05 | $0.02 | $-0.13 | $-0.28 | $-0.49 | $-0.46 | $-0.31 | $-0.17 | $-0.32 | $-0.25 | $-0.23 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, ARS Pharmaceuticals's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to SPRY previous annual EPS of $NaN (undefined).
ARS Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| HEPA | Hepion Pharmaceuticals | $0.69 | $70.00 | 10044.93% | Buy |
| INAB | IN8bio | $0.32 | $14.00 | 4275.00% | Buy |
| DRMA | Dermata Therapeutics | $1.08 | $6.00 | 455.56% | Buy |
| IMMX | Immix Biopharma | $1.70 | $7.00 | 311.76% | Buy |
| CUE | Cue Biopharma | $1.08 | $4.33 | 300.93% | Buy |
| CNSP | CNS Pharmaceuticals | $0.13 | $0.50 | 284.62% | - |
| ZURA | Zura Bio | $3.15 | $10.00 | 217.46% | Buy |
| TCRX | TScan Therapeutics | $4.21 | $12.00 | 185.04% | Buy |
| ANNX | Annexon | $5.46 | $14.00 | 156.41% | Buy |
| SPRY | ARS Pharmaceuticals | $13.79 | $23.33 | 69.18% | Buy |
| WVE | Wave Life Sciences | $14.21 | $22.14 | 55.81% | Buy |
| PALI | Palisade Bio | $2.43 | $1.50 | -38.27% | Buy |